Krka Enjoys 9% Pharma Sales Growth At The Half-Way Stage
Growth In All Six Geographic Segments Aids Krka; EBITDA Margin Above Guidance
Executive Summary
Krka insisted that its margins were “stable and high,” as the Slovenian firm reported another solid quarter.